Page 180 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.1. Descriptive characteristics of the epidemiologic studies considered relevant to KQ1 (continued)
Author Database Start End year Sample size Eligibility criteria
Year year
uid
66
Harlan CaPSURE 1989 2000 5365 Patients with biopsy-confirmed prostate adenocarcinoma, localized stage
2003 (402 received WW) (T3a or lower, N0 M0) who chose WW or active treatment within 9 mo of
14532780 diagnosis. Patients who waited more than 9 mo after diagnosis before
initiating active treatment and those who received active treatment before or
within 6 mo after initiating WW were excluded from the analysis. Active
treatment was defined as RP, EBRT, interstitial RT, cryotherapy, or ADT.
67
Cooperberg CaPSURE 1989 2001 1990 Excluded patients with unknown PSA at diagnosis, diagnostic biopsy Gleason
2004 score, and/or clinical T stage. Excluded patients with unknown primary
15169800 treatment, and those receiving cryotherapy as primary therapy (this group
accounted for 2% of patients since 1996; 68% of cryotherapy treated patients
were treated at a single practice site in the early 1990s). Only low-risk
prostate cancer patients were analyzed for the temporal trends of clinical
characteristics or treatments received.
68
Cooperberg CaPSURE 1990 2006 10,385 Excluded those diagnosed before 1990, those with metastatic or locally
2007 advanced disease (clinical stage T3b or higher) and those with missing data
17644125 on PSA, T stage or biopsy Gleason score. Localized biopsy-proven prostate
adenocarcinoma. Information relevant to this review is only reported for “low-
risk” prostate cancer, defined as PSA≤10 ng/ml, Gleason score≤6 and
clinical stage T1/2a.
90
Cooperberg CaPSURE 1990 2007 10,808 Localized prostate cancer, excluding metastatic or locally advanced
2008 [3372 were (≥T3bN0M0) disease, missing PSA, clinical T stage, or Gleason score data.
18369637 considered high risk] Results for trends over time were reported only among the high risk subset of
patients. High risk was defined as stage T2c/T3a, PSA >20ng/mL, or Gleason
score ≥8.
69
Cooperberg CaPSURE 1990 2008 11,892 Biopsy-proven prostate cancer. Excluded advanced disease (stage higher
2010 than T3a N0 M0); diagnosed before 1990; those from sites contributing <30
20124165 pts; and those receiving treatments other than RP, EBRT, BT, cryoablation,
WW/AS or ADT or with unknown primary treatment.
70
Shah CaPSURE 1995 2004 6450 Unselected men with biopsy-proven prostate adenocarcinoma. Enrolled in
2008 CaPSURE within 6 mo of diagnosis with complete clinical information (PSA,
17997437 Gleason score and clinical stage) and complete followup information.
Excluded patients with fewer than 6 biopsy cores or unavailable biopsy
details.
71
Greene CaPSURE 1997 2003 3003 Patients with biopsy-proven prostate cancer; availability of pretreatment
2005 demographics and QoL data.
16194711

C-8